TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16840657
Drug: rhIL-6 infusion
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-6 infusion (5 microg/h for 3 h)
Study: 15383370
Drug: rhIL-6 infusion
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-6 infusion
Study: 9270508
Drug: Tretinoin emollient
Normalized name: Tretinoin Emollient Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin emollient cream 0.05% applied three times weekly
Study: 9270508
Drug: Tretinoin emollient
Normalized name: Tretinoin Emollient Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin emollient cream 0.05% applied once weekly
Study: 18831420
Drug: Sham gel
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham gel
Study: 28845523
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg weekly subcutaneous for 12 weeks
Study: 18327364
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% 3 times daily and Timolol 0.5% twice daily
Study: 15771757
Drug: Ursofalk suspension
Normalized name: ursodiol Oral Capsule [Ursofalk]
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursofalk suspension
Study: 15771757
Drug: Ursofalk suspension
Normalized name: ursodiol Oral Capsule [Ursofalk]
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursofalk suspension and capsules
Study: 1658138
Drug: UK 79300
Normalized name: UK-390957
DrugBank: UK-390957 (DB11719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 79300 25 mg every 12 h (group 1)
Study: 6302937
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Human-fibroblast-derived (Beta) interferon (Hu1FN-B) at a dosage of 2-5 x 10(5) reference units daily for one week.
Study: 20406224
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg
Study: 12867226
Drug: Hydroxyzine 50
Normalized name: hydroxyzine hydrochloride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 50 mg
Study: 15204391
Drug: Desmopressin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.4 mg)
Study: 15204391
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (after 4 weeks of monotherapy)
Study: 12362011
Drug: Remaining subjects
Normalized name: Remain Gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaining subjects in treatment group (after factoring out counseling)
Study: 12362011
Drug: Those who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Those who made at least one attempt to quit in treatment group
Study: 9220235
Drug: 3% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% acyclovir ointment
Study: 20499046
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg twice daily for 16 weeks
Study: 18340440
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic administered to the vocal folds
Study: 12152675
Drug: Atorvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 20 mg/day
Study: 27578305
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate gel (IMB) for 3 days
Study: 27578305
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with methyl aminolevulinate (MAL-PDT) for a single session
Study: 15949921
Drug: Deramciclane 30
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane 30 mg/day
Study: 10396388
Drug: Pre-operative assessment
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative assessment by a trained ophthalmic nurse at the peripheral clinic
Study: 7552478
Drug: CD4‐IgG 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4‐IgG 30, 100, or 300 micrograms/kg weekly; 1,000 micrograms/kg once, twice, or three times per week; or 3,000 micrograms/kg twice weekly
Study: 27552000
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment based on TNF alpha inhibitors and low‐carbohydrates calorie‐restricted diet
Study: 27552000
Drug: TNF‐alpha inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐alpha inhibitors
Study: 26686262
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message reminders (daily tailored messages for 4 days)
Study: 21982723
Drug: Sublingual testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual testosterone 0.25 mg
Study: 21982723
Drug: Sublingual testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual testosterone (all doses)
Study: 11113749
Drug: Neoadjuvant luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant luteinizing hormone-releasing hormone-analogue treatment
Study: 1354948
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (0.15 mg/kg x 2)
Study: 1354948
Drug: Aminophylline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (3 mg/kg) infusion
Study: 3073045
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (Rocephin), administered once daily for a mean duration of 9.9 days.
Study: 3073045
Drug: Ampicillin or
Normalized name: ampicillin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin or ampicillin plus chloramphenicol, administered in 4 doses/day for a mean duration of 12.3 days.
Study: 28163732
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy
Study: 27655261
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives for adherence to antipsychotic depot medication
Study: 29401355
Drug: Animal-Assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-Assisted Therapy (AAT)
Study: 24020828
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocol
Study: 23129179
Drug: Orally inhaled
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally inhaled allergen
Study: 23129179
Drug: Orally inhaled
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally inhaled diluent placebo
Study: 17015810
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (SGAs) other than clozapine
Study: 19389331
Drug: First-generation antipsychotics
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotics (FGAs)
Study: 23602068
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg intravenous methylprednisolone
Study: 27604388
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg intravenous methylprednisolone after anaesthesia induction
Study: 23250605
Drug: Levodopa/carbidopa (nakom)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa (nakom) treatment in Group 1 (230 patients not previously treated with levodopa)
Study: 23250605
Drug: Levodopa/carbidopa (nakom)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa (nakom) treatment in Group 2 (262 patients treated with levodopa/carbidopa needing higher doses)
Study: 23250605
Drug: Levodopa/carbidopa (nakom)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa (nakom) treatment in Group 3 (271 patients treated earlier with other levodopa preparations)
Study: 19114414
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg valerian (Valeriana officinalis, n = 7)
Study: 15516023
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride oral tablet (20 mg)
Study: 9828987
Drug: Graded exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exercise and 20 mg fluoxetine
Study: 9828987
Drug: Appointments and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appointments and placebo drug
Study: 1265295
Drug: Intrauterine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine administration of 5 mg PGF2alpha
Study: 25846982
Drug: In-person behavior
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person behavior therapy
Study: 21257798
Drug: INCB018424 phosphate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB018424 phosphate, 25 mg bid and 100 mg qd
Study: 21257798
Drug: Pharmacodynamics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacodynamics of INCB018424
Study: 12874502
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of methylphenidate
Study: 2268938
Drug: Routine drugs
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drugs only
Study: 6992827
Drug: Immunotherapy consisting
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy consisting of intradermal BCG plus allogeneic cells
Study: 20018913
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance treatment
Study: 29519541
Drug: Caffeine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (20 mg/kg loading dose followed by 5 mg/kg/day)
Study: 29519541
Drug: Placebo (blinded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (blinded loading dose of caffeine)
Study: 30151821
Drug: Apixaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily thereafter)
Study: 26623651
Drug: Tilt table
Normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt table therapy with integrated stepping device (Erigo)
Study: 24043276
Drug: Intervention (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (18 1-hour home-based therapy sessions)
Study: 21373908
Drug: Measured resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measured resection technique (MG)
Study: 16406273
Drug: Pethidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (100 mg)
Study: 27543533
Drug: TPVB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPVB with ropivacaine 0.5%, 25 ml
Study: 20339099
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg/day (LOS)
Study: 20339099
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg/day (LOS) plus Hydrochlorothiazide 25 mg/day (LOS/HCT)
Study: 18657671
Drug: Sotalol (S)
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sotalol (S) 167 ± 66 mg/d
Study: 18657671
Drug: Beta-blockers (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (BB) 62 ± 26 mg/d for atenolol and 104 ± 47 mg/d for metoprolol
Study: 15668282
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (8 cycles of mitoxantrone, methotrexate with tamoxifen)
Study: 7665721
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg
Study: 9283163
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 mg
Study: 27530980
Drug: Bimanual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual therapy (standard practice)
Study: 25884824
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application (SIMPLe) on top of treatment as usual
Study: 17724363
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg i.v. pantoprazole infused for 15 minutes
Study: 11157022
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment (ICE every 2 weeks with filgrastim and autologous blood reinfusion)
Study: 11157022
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ICE every 4 weeks)
Study: 9778080
Drug: Front-loaded alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Front-loaded alteplase infusion (100 mg total: 15 mg bolus, then 50 mg over 30 minutes, then 35 mg over 60 minutes)
Study: 27365387
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies to C. difficile toxins A and B (not detailed in dosage or duration)
Study: 24056586
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid (Hartmann's solution)
Study: 20558112
Drug: Neuropsychological test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropsychological test battery before antiepileptic treatment
Study: 18524643
Drug: Foam sclerosant
Normalized name: SCLEROSING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foam sclerosant (3% polidocanol foam, 2-2.5 ml injected)
Study: 18524643
Drug: Liquid sclerosant
Normalized name: SCLEROSING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid sclerosant (3% polidocanol liquid, 2-2.5 ml injected)
Study: 19606472
Drug: Donepezil (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5-10 mg/day)
Study: 11153670
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice daily
Study: 1532615
Drug: Ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 500 mg four times daily
Study: 3924399
Drug: Sodium-hydrogen divalproate
Normalized name: sodium hydrogen sulfite
DrugBank: Sodium bisulfite (DB14015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-hydrogen divalproate (SHD) 250 mg
Study: 3924399
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 300 mg
Study: 2905991
Drug: cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 800 mg
Study: 24448652
Drug: Omeprazole/sodium bicarbonate
Normalized name: OMEPRAZOLE/SODIUM BICARBONATE
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole/sodium bicarbonate (Zegerid(®)) 40 mg once daily for 8 weeks (nighttime dosing)
Study: 19095028
Drug: Live-attenuated influenza
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated influenza vaccine
Study: 10189007
Drug: Digitalis 0.75‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis 0.75‐1 mg i.v. plus quinidine 1100 mg (D+Q)
Study: 2316591
Drug: Amoxicillin treatment
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin treatment for 3 days
Study: 2316591
Drug: Amoxicillin treatment
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin treatment for 10 days
Study: 2316591
Drug: Cephalexin or
Normalized name: cephalexin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin or nitrofurantoin therapy for 7 days (for amoxicillin-resistant infections)
Study: 20958183
Drug: 1% voriconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% voriconazole (VZ) single dose
Study: 20958183
Drug: 0.1% voriconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% voriconazole (VZ) single dose
Study: 20958183
Drug: 1% voriconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% voriconazole (VZ) multidose (hourly)
Study: 23121439
Drug: Conventional strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional strategy without monitoring and drug adjustment.
Study: 23121439
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (monitoring and conventional treatment).
Study: 19758398
Drug: Ondansetron 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.2 mg/kg
Study: 10589108
Drug: Quick Relaxation
Normalized name: Cal-Quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quick Relaxation Technique (QRT) in conjunction with analgesics
Study: 10589108
Drug: Analgesics without
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics without relaxation exercises
Study: 30532289
Drug: Inactivated BRSV
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated BRSV vaccine
Study: 30532289
Drug: Modified-live (MLV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-live (MLV) BRSV vaccine
Study: 24495406
Drug: Trazodone 50
Normalized name: traZODone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50 mg once daily at 10:00 P.M. for 2 weeks
Study: 16101168
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 IU subcutaneously once weekly plus oral iron 200 mg elemental iron once daily
Study: 16101168
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron 200 mg elemental iron once daily
Study: 8184044
Drug: Conventional-dose thin-section
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose thin-section CT (340-mAs)
Study: 30501868
Drug: Dose-adjusted EPOCH-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted EPOCH-R (DA-EPOCH-R) administered for six cycles with CNS prophylaxis
Study: 18362256
Drug: New treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatments
Study: 18362256
Drug: Statistically significant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistically significant trials favoring new or standard treatments
Study: 10333895
Drug: Baseline ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline ACE inhibitor usage
Study: 31529007
Drug: Behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral and pelvic floor muscle therapy combined with midurethral sling (n=209)
Study: 26004044
Drug: Normal exponential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal exponential taper
Study: 21955196
Drug: Ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon 8 mg
Study: 12923410
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8-16 mg once daily)
Study: 9816717
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine 6 ml at room temperature (Group B)
Study: 9816717
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine 5 ml + 7% sodium bicarbonate 1 ml at room temperature (Group C)
Study: 7621841
Drug: Mianserin 60-90
Normalized name: mianserin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 60-90 mg daily
Study: 6458872
Drug: Imipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (75 mg/day)
Study: 6458872
Drug: Zimelidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (200 mg/day)
Study: 6458872
Drug: Zimelidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (100 mg/day)
Study: 28104096
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment (control group)
Study: 29101117
Drug: Double-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose clopidogrel (600 mg day 1; 150 mg days 2-7; then 75 mg daily)
Study: 20817281
Drug: Double-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose clopidogrel
Study: 19443826
Drug: 12-week twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week twice-weekly heart health program
Study: 15026868
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol (0.3 g/kg in 250 mL water)
Study: 15026868
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol (7.5 mg/kg/minute in 250 mL saline for 40 minutes)
Study: 15026868
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline 250 mL infused for 40 minutes)
Study: 15026868
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intravenous alcohol
Study: 2572475
Drug: Ketoconazole orally
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole orally (400 mg/day for 5 days)
Study: 2572475
Drug: Nystatin vaginal
Normalized name: Nystatin Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin vaginal pessaries (100,000 units twice/day for 7 days)
Study: 26151563
Drug: Relief ACP
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relief ACP (desensitizing gel)
Study: 26151563
Drug: UltraEZ (desensitizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: UltraEZ (desensitizing gel)
Study: 26151563
Drug: Control (30-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (30-minute treatment without any treatment material)
Study: 17650536
Drug: Integrated Psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Psychological Therapy (IPT) program